Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
Because of its pharmacokinetic characteristics, such as short half-life and its safety
profile, esmolol hydrochloride is a beta blocker suitable for venous use in the form of
continuous infusion. Strategies that improve the blood pressure control of patients with
hemorrhagic stroke during the first hours of hospitalization are determinant in controlling
the hematoma expansion and determining factor in its prognosis. This study was designed with
the objective of evaluating the beneficial effects of combining esmolol hydrochloride with
sodium nitroprusside for the blood pressure control of participants with hemorrhagic stroke.